PMID- 16817689
OWN - NLM
STAT- MEDLINE
DCOM- 20060809
LR  - 20191026
IS  - 1092-0684 (Electronic)
IS  - 1092-0684 (Linking)
VI  - 9
IP  - 6
DP  - 2000 Dec 15
TI  - Recombinant adenovirus-transduced dendritic cell immunization in a murine model 
      of central nervous system tumor.
PG  - e6
AB  - OBJECT: Dendritic cells (DCs) are potent antigen-presenting cells that have been 
      shown to play a critical role in the initiation of host immune responses against 
      tumor antigens. In this study, a recombinant adenovirus vector encoding the 
      melanoma-associated antigen, MART-1, was used to transduce murine DCs, which were 
      then tested for their ability to activate cytotoxic T lymphocytes (CTLs) and 
      induce protective immunity against B16 melanoma tumor cells implanted 
      intracranially. METHODS: Genetic modification of murine bone marrow-derived DCs 
      to express MART-1 was achieved through the use of an E1-deficient, recombinant 
      adenovirus vector (AdVMART1). Sixty-two C57BL/6 mice were immunized by 
      subcutaneous injection of AdVMART-1-transduced DCs (23 mice), untransduced DCs 
      (17 mice), or sterile saline (22 mice). Using the B16 murine melanoma, which 
      naturally expresses the MART-1 antigen, all the mice were then challenged 
      intracranially with viable, unmodified syngeneic B16 tumor cells 7 days later. 
      Splenocytes obtained from representative animals in each group were harvested for 
      standard cytotoxicity and enzyme-linked immunospot assays. The remaining mice 
      were followed for survival. Immunization of C57BL/6 mice with DCs transduced with 
      AdVMART1-DC elicited the development of antigenspecific CTL responses. As 
      evidenced by a prolonged survival curve when compared with control-immunized mice 
      harboring intracranial B16 tumors, AdMART1-DC vaccination was able to elicit 
      partial protection against central nervous system (CNS) tumor challenge in vivo. 
      However, this CNS antitumor immunity was weaker than that previously demonstrated 
      against subcutaneous B16 tumors in which the same vaccination strategy was used. 
      CONCLUSIONS: These data suggest that immune responses generated against CNS 
      tumors by DC-based vaccines may be different from those obtained against 
      subcutaneous tumors.
FAU - Broder, H
AU  - Broder H
AD  - Division of Neurosurgery, University of California at Los Angeles School of 
      Medicine, Los Angeles, California 90095-6901, USA.
FAU - Anderson, A
AU  - Anderson A
FAU - Odesa, S K
AU  - Odesa SK
FAU - Kremen, T J
AU  - Kremen TJ
FAU - Liau, L M
AU  - Liau LM
LA  - eng
GR  - CA82666/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20001215
PL  - United States
TA  - Neurosurg Focus
JT  - Neurosurgical focus
JID - 100896471
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cytokines)
RN  - 0 (MART-1 Antigen)
RN  - 0 (MLANA protein, human)
RN  - 0 (Mlana protein, mouse)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Animals
MH  - Antigens, Neoplasm
MH  - Brain Neoplasms/*immunology/pathology/prevention & control
MH  - Cells, Cultured
MH  - Cytokines/metabolism
MH  - Dendritic Cells/cytology/*immunology/metabolism
MH  - *Disease Models, Animal
MH  - Female
MH  - Humans
MH  - Immunization
MH  - MART-1 Antigen
MH  - Melanoma/*immunology/pathology/prevention & control
MH  - Mice
MH  - *Mice, Inbred C57BL
MH  - Neoplasm Proteins/genetics/immunology
MH  - Neoplasm Transplantation
MH  - Spleen/cytology
MH  - T-Lymphocytes, Cytotoxic/immunology/metabolism
MH  - Transduction, Genetic
MH  - Xenograft Model Antitumor Assays
EDAT- 2006/07/05 09:00
MHDA- 2006/08/10 09:00
CRDT- 2006/07/05 09:00
PHST- 2006/07/05 09:00 [pubmed]
PHST- 2006/08/10 09:00 [medline]
PHST- 2006/07/05 09:00 [entrez]
AID - 090606 [pii]
AID - 10.3171/foc.2000.9.6.7 [doi]
PST - epublish
SO  - Neurosurg Focus. 2000 Dec 15;9(6):e6. doi: 10.3171/foc.2000.9.6.7.